Vascular Endothelial Growth Factor Biology and Its Potential as a Therapeutic Target in Rheumatic Diseases.

Abstract

Rheumatic diseases constitute a diversified group of diseases distinguished by arthritis and often involve other organs. The affected individual has low quality of life, productivity even life-threatening in some severe conditions. Moreover, they impose significant economic and social burdens. In recent years, the patient outcome has been improved significantly due to clearer comprehension of the pathology of rheumatic diseases and the effectiveness of "treat to target" therapies. However, the high cost and the adverse effects are the concerns and full remissions are not often observed. One of the main processes that contributes to the pathogenesis of rheumatic diseases is angiogenesis. Vascular endothelial growth factor (VEGF), a central mediator that regulates angiogenesis, has different isoforms and functions in various physiological processes. Increasing evidence suggests an association between the VEGF system and rheumatic diseases. Anti-VEGF and VEGF receptor (VEGFR) therapies have been used to treat several cancers and eye diseases. This review summarizes the current understanding of VEGF biology and its role in the context of rheumatic diseases, the contribution of VEGF bioavailability in the pathogenesis of rheumatic diseases, and the potential implications of therapeutic approaches targeting VEGF for these diseases.

• Authors: Thi Hong Van Le, Sang-Mo Kwon
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 22 Issue 10 (May 20 2021) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 34065409 (Publication Type: Journal Article, Review)

Chemical References

• Vascular Endothelial Growth Factors
• Receptors, Vascular Endothelial Growth Factor

Topics

• Animals
• Humans
• Neovascularization, Pathologic (metabolism)
• Receptors, Vascular Endothelial Growth Factor (metabolism)
• Rheumatic Diseases (metabolism)
• Vascular Endothelial Growth Factors (metabolism)